Opus Genetics (NASDAQ:IRD) Upgraded at Zacks Research

Opus Genetics (NASDAQ:IRD) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other analysts have also issued reports on the company. Royal Bank Of Canada lowered their price target on Opus Genetics from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Friday, August 7th. Leerink Partners started coverage on Opus Genetics in a research report on Thursday, May 21st. They set an “outperform” rating and a $10.00 target price for the company. Chardan Capital reiterated a “buy” rating and issued a $13.00 target price on shares of Opus Genetics in a report on Monday, July 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Opus Genetics in a research report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Opus Genetics in a research note on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Opus Genetics has a consensus rating of “Moderate Buy” and an average target price of $10.69.

Opus Genetics Trading Down 3.1%

NASDAQ IRD opened at $3.76 on Tuesday. The stock has a market cap of $310.76 million, a PE ratio of -2.79 and a beta of 0.59. Opus Genetics has a 12 month low of $1.04 and a 12 month high of $5.81. The company’s 50-day moving average price is $3.79 and its 200-day moving average price is $4.15.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $2.63 million. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%. As a group, sell-side analysts forecast that Opus Genetics will post -1.05 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO George Magrath sold 9,475 shares of the business’s stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total value of $27,951.25. Following the completion of the transaction, the chief executive officer directly owned 1,731,869 shares of the company’s stock, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 1,700,000 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $4.35, for a total value of $7,395,000.00. Following the sale, the director owned 3,792,171 shares of the company’s stock, valued at $16,495,943.85. This trade represents a 30.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 1,729,331 shares of company stock valued at $7,481,629. 11.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Opus Genetics

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Opus Genetics in the 2nd quarter valued at about $12,809,000. Balyasny Asset Management L.P. bought a new position in shares of Opus Genetics during the 4th quarter worth approximately $5,463,000. Millennium Management LLC bought a new position in shares of Opus Genetics during the 4th quarter worth approximately $4,025,000. ADAR1 Capital Management LLC lifted its position in Opus Genetics by 4,522.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company’s stock valued at $8,413,000 after acquiring an additional 1,809,004 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its stake in Opus Genetics by 42.9% in the fourth quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock valued at $9,610,000 after acquiring an additional 1,435,407 shares in the last quarter. 14.97% of the stock is currently owned by institutional investors.

Key Stories Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Analysts raised earnings estimates: Brookline Capital Markets lifted its projections for Q3 2026 EPS to $(0.15) from $(0.18), FY2026 EPS to $(0.87) from $(1.31), FY2027 EPS to $(0.56) from $(0.77), and FY2028 EPS to $(0.61) from $(0.68). These revisions indicate expectations for narrower losses. Opus Genetics analyst estimates
• Positive Sentiment: HC Wainwright remains bullish: The firm raised its Q4 2026 EPS forecast to $(0.09) from $(0.14), increased its FY2026 estimate to $(1.03) from $(1.18), and raised FY2027 expectations to $(0.40) from $(0.46). It maintains a Buy rating and an $8 price target, well above the stock’s recent trading level.
• Positive Sentiment: Long-term profitability is projected: HC Wainwright forecasts positive EPS of $0.05 in FY2029 and $0.27 in FY2030, while Brookline projects $0.62 in FY2030. These estimates support a potential long-term recovery if Opus successfully advances its pipeline and controls spending.
• Neutral Sentiment: Short-interest data provides little signal: Reported short interest was zero shares with a zero-day days-to-cover ratio, suggesting the data is incomplete or unreliable rather than indicating meaningful investor positioning.
• Negative Sentiment: Losses remain substantial: Analysts still expect Opus Genetics to post a full-year loss of approximately $(1.05) to $(1.09) per share. The latest quarter also showed very low revenue of $0.76 million versus a $2.63 million consensus estimate, despite a modest EPS beat.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.